CPAx: Responsiveness and Minimal Clinically Important Difference
- Disease/Condition
- Muscle Weakness,Critical Illness Myopathy,Critical Illness Polyneuropathy,Critical Illness Polyneuromyopathy,Physical Inactivity
- Study type
- Observational
- Primary sponsor
- Insel Gruppe AG, University Hospital Bern
- Location
- Bern, Switzerland
- Phase
- N/A
- Start date
- May 01, 2024
- End date
- Oct 01, 2025
- Enrollment
- 120 participants
Chelsea Critical Care Physical Assessment tool (CPAx) change score
Intensive care unit (ICU) acquired weakness is a common complication associated with
 long-term physical impairments in survivors of a critical illness. The Chelsea Critical Care
 Physical Assessment tool (CPAx) is a valid and reliable instrument for physical function and
 activity in critically ill patients at risk for muscle weakness. However, its ability to
 measure change over time (responsiveness) and the minimal clinically important difference
 (MCID) have not yet been rigorously investigated. This multi-centre, mixed-methods,
 longitudinal cohort study therefore aims to establish responsiveness and the MCID of the CPAx
 in the target population from ICU baseline to ICU and hospital discharge. The study uses
 routine data from standard physiotherapy sessions like mobility, function and activity with
 no additional burden for critically ill adults. The investigators expect the CPAx to be
 responsive allowing its use as a primary outcome in future effectiveness trials for the
 treatment of ICU-acquired weakness using the newly established MCID for sample size
 calculation. A high quality, rigorously tested measurement tool for physical function and
 activity in the ICU should benefit researchers, clinicians and patients.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06419699
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06419699 through Pure Global AI's free database. This phase not specified trial is sponsored by Insel Gruppe AG, University Hospital Bern and is currently Not yet recruiting. The study focuses on Muscle Weakness,Critical Illness Myopathy,Critical Illness Polyneuropathy,Critical Illness Polyneuromyopathy,Physical Inactivity. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.